![Laura Brass](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Laura Brass
Direktor/Vorstandsmitglied bei
Immunitas Therapeutics, Inc.
Profil
Laura Brass is currently Managing Director at Novartis Venture Funds (USA) since 2018 and at Novartis Venture Fund since 2018.
Dr. Brass is also Director at Anokion SA since 2019, and Director at Kanyos Bio, Inc. and Immunitas Therapeutics, Inc. Former roles include Managing Director at MPM BioImpact LLC from 2015 to 2018, Director-Business Development at the Office of Technology Development, Director at ESCAPE Bio, Inc., Senior Manager at Elixir Pharmaceuticals, Inc., and Senior Vice President-Business Development at TriNetX, LLC.
Education includes undergraduate studies at the University of Missouri and an MBA and a doctorate from The University of Chicago.
Aktive Positionen von Laura Brass
| Unternehmen | Position | Beginn |
|---|---|---|
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Private Equity Investor | 01.10.2018 |
Anokion SA
 Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Direktor/Vorstandsmitglied | 11.09.2019 |
Immunitas Therapeutics, Inc.
 Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Develops single cell genomic-based drugs | Direktor/Vorstandsmitglied | - |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Direktor/Vorstandsmitglied | - |
Novartis Venture Funds
 Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Private Equity Investor | 01.10.2018 |
Ehemalige bekannte Positionen von Laura Brass
| Unternehmen | Position | Ende |
|---|---|---|
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Private Equity Investor | 30.09.2018 |
ESCAPE Bio, Inc.
 ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease | Direktor/Vorstandsmitglied | - |
Elixir Pharmaceuticals, Inc.
 Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases | Corporate Officer/Principal | - |
TriNetX, LLC
 TriNetX, LLC Data Processing ServicesTechnology Services Provides healthcare and life science data & platform solutions | Corporate Officer/Principal | - |
| ░░░░░░ ░░ ░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Laura Brass
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
62
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
University of Missouri
 University of Missouri Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Elixir Pharmaceuticals, Inc.
Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases | Miscellaneous |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Finance |
Office of Technology Development
 Office of Technology Development Investment ManagersFinance Office of Technology Development invests in companies located in the United States. The firm focuses on health and technology sectors. It participates in early-stage transactions. | Finance |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Finance |
Anokion SA
Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Health Technology |
TriNetX, LLC
TriNetX, LLC Data Processing ServicesTechnology Services Provides healthcare and life science data & platform solutions | Technology Services |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Health Technology |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease | Health Technology |
Immunitas Therapeutics, Inc.
Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Develops single cell genomic-based drugs | Health Technology |
